{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:01:53Z","timestamp":1773741713744,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95038","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:05:16Z","timestamp":1761041116000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Capillary Leak Syndrome: A Rare but Life-Threatening Immune-Related Adverse Event"],"prefix":"10.7759","author":[{"given":"Roxanne K","family":"Branford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Hernandez Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana P","family":"Gonzalez Frontera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Ledea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00571-5","article-title":"Systemic capillary leak syndrome","volume":"10","author":"Druey KM","year":"2024","unstructured":"Druey KM, Arnaud L, Parikh SM. Systemic capillary leak syndrome. Nat Rev Dis Primers. 2024, 10:86. 10.1038\/s41572-024-00571-5","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary leak syndrome: etiologies, pathophysiology, and management","volume":"92","author":"Siddall E","year":"2017","unstructured":"Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017, 92:37-46. 10.1016\/j.kint.2016.11.029","journal-title":"Kidney Int"},{"key":"ref3","article-title":"Pembrolizumab","author":"Flynn JP","year":"2025","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref4","unstructured":"National Cancer Institute. NCI dictionary of cancer terms: capillary leak syndrome. (2025). https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/capillary-leak-syndrome."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2021.01.004","article-title":"Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction","volume":"5","author":"Qin H","year":"2021","unstructured":"Qin H, Vlaminck B, Owoyemi I, Herrmann SM, Leung N, Markovic SN. Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction. Mayo Clin Proc Innov Qual Outcomes. 2021, 5:670-4. 10.1016\/j.mayocpiqo.2021.01.004","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref6","unstructured":"Cleveland Clinic. Complete blood count (CBC). (2025). Accessed: July 29, 2025: https:\/\/my.clevelandclinic.org\/health\/diagnostics\/4053-complete-blood-count."},{"key":"ref7","unstructured":"National Library of Medicine. Capillary leak syndrome. (2025). Accessed: July 19, 2025: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/68019559."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-2-201007200-00005","article-title":"Narrative review: the systemic capillary leak syndrome","volume":"153","author":"Druey KM","year":"2010","unstructured":"Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010, 153:90-8. 10.7326\/0003-4819-153-2-201007200-00005","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-7-201104050-00004","article-title":"The systemic capillary leak syndrome: a case series of 28 patients from a European registry","volume":"154","author":"Gousseff M","year":"2011","unstructured":"Gousseff M, Arnaud L, Lambert M, et al.. The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med. 2011, 154:464-71. 10.7326\/0003-4819-154-7-201104050-00004","journal-title":"Ann Intern Med"},{"key":"ref11","unstructured":"National Comprehensive Cancer Network. Immunotherapy side effects: immune checkpoint inhibitors. (2024). Accessed: September 9, 2025: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/immunotherapy-checkpoint-patient.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.05.023","article-title":"Intravenous immunoglobulins improve survival in monoclonal gammopathy-associated systemic capillary-leak syndrome","volume":"130","author":"Pineton de Chambrun M","year":"2017","unstructured":"Pineton de Chambrun M, Gousseff M, Mauhin W, et al.. Intravenous immunoglobulins improve survival in monoclonal gammopathy-associated systemic capillary-leak syndrome. Am J Med. 2017, 130:1219.e19-27. 10.1016\/j.amjmed.2017.05.023","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397454-pembrolizumab-induced-capillary-leak-syndrome-a-rare-but-life-threatening-immune-related-adverse-event","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:05:18Z","timestamp":1761041118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397454-pembrolizumab-induced-capillary-leak-syndrome-a-rare-but-life-threatening-immune-related-adverse-event"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.95038","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}